DCTH

Business Context and Reporting Period

Company: Delcath Systems, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2010
Business Stage: Development Stage Company
Overview: Delcath is a specialty pharmaceutical and medical device company focused on oncology. Its proprietary system for chemosaturation therapy is designed to administer high-dose chemotherapy to diseased organs while controlling systemic exposure. The company has not yet received FDA or foreign regulatory approval for commercial sale. It recently concluded a Phase III metastatic melanoma study and is conducting a multi-arm Phase II trial for liver cancers.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately $13.0 million (148%) compared to the six months ended June 30, 2009. This was driven by a $9.4 million increase in total costs and a $3.6 million increase in warrant derivative instrument expense.
• Expense Growth:
  • General and Administrative (G&A): Increased by $5.5 million to $6.2 million, attributed to staffing increases in Marketing, Sales, Finance, and Manufacturing to support commercialization efforts.
  • Research and Development (R&D): Increased by $3.8 million to $7.5 million due to hiring, operational expansion of the Queensbury facility, and regulatory preparation.
• Warrant Liability: The company recorded a pre-tax derivative instrument income of $8.05 million due to the change in fair value of the warrant liability. Additionally, $8.54 million of the liability was reclassified to stockholders' equity following the exercise of 861,889 warrants.
• Headcount: Full-time employees increased from 7 in Q2 2009 to 32 in Q2 2010.
• Liquidity: Cash and cash equivalents decreased from $35.5 million at year-end 2009 to $23.9 million at June 30, 2010, primarily due to operating cash burn and investments in certificates of deposit ($3.2 million).

Outlook, Risks, and Management Commentary

• Regulatory Status: The company initiated a rolling New Drug Application (NDA) submission to the FDA in late April 2010 for the treatment of metastatic melanoma to the liver. The system is not yet approved for commercial sale.
• Clinical Results: The Phase III clinical trial successfully met its primary endpoint, showing a statistically significant longer median hepatic progression-free survival (214 days vs. 70 days) compared to best alternative care.
• Liquidity Outlook: Management believes it has sufficient capital to fund operations through 2010. However, the company expects to continue incurring significant losses and will need to raise additional capital via equity, debt, or strategic alliances to fund future development and commercialization.
• Strategic Partnerships: The company entered a research and distribution agreement with Chi-Fu Trading Co., Ltd. for Taiwan, receiving $300,000 in deferred revenue. It is actively pursuing partners in China, Korea, Japan, and Europe.
• Risks: Key risks include the uncertainty of FDA approval, the need for additional financing, and the potential for clinical trial delays. The company has no revenue and relies entirely on capital markets.

Investor Verification Checklist

• Capital Runway: Verify if the $23.9 million cash balance is sufficient to cover the projected burn rate through the FDA decision timeline, given the increased operating expenses.
• Warrant Liability Volatility: Monitor the fair value adjustments of the $10.7 million warrant liability, as these non-cash items significantly impact reported net loss and equity.
• Regulatory Timeline: Confirm the status of the rolling NDA submission and any potential FDA requests for additional data that could delay approval.
• Commercialization Readiness: Assess the progress of the manufacturing facility in Queensbury and the hiring of the sales force relative to the anticipated approval date.
• Deferred Revenue: Track the recognition of the $300,000 deferred revenue from the Chi-Fu agreement, which is contingent on regulatory milestones.